JP6112569B2 - キメラ２重鎖核酸 - Google Patents

キメラ２重鎖核酸 Download PDF

Info

Publication number
JP6112569B2
JP6112569B2 JP2014528740A JP2014528740A JP6112569B2 JP 6112569 B2 JP6112569 B2 JP 6112569B2 JP 2014528740 A JP2014528740 A JP 2014528740A JP 2014528740 A JP2014528740 A JP 2014528740A JP 6112569 B2 JP6112569 B2 JP 6112569B2
Authority
JP
Japan
Prior art keywords
nucleic acid
pharmaceutical composition
acid strand
nucleotide
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014528740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502134A5 (enExample
JP2015502134A (ja
Inventor
隆徳 横田
隆徳 横田
一隆 仁科
一隆 仁科
聡 小比賀
聡 小比賀
水澤　英洋
英洋 水澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokyo Medical and Dental University NUC
University of Osaka NUC
Original Assignee
Osaka University NUC
Tokyo Medical and Dental University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, Tokyo Medical and Dental University NUC filed Critical Osaka University NUC
Priority to JP2014528740A priority Critical patent/JP6112569B2/ja
Publication of JP2015502134A publication Critical patent/JP2015502134A/ja
Publication of JP2015502134A5 publication Critical patent/JP2015502134A5/ja
Application granted granted Critical
Publication of JP6112569B2 publication Critical patent/JP6112569B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2014528740A 2011-12-16 2012-12-17 キメラ２重鎖核酸 Active JP6112569B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014528740A JP6112569B2 (ja) 2011-12-16 2012-12-17 キメラ２重鎖核酸

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2011275488 2011-12-16
JP2011275488 2011-12-16
PCT/JP2012/083180 WO2013089283A1 (en) 2011-12-16 2012-12-17 Chimeric double-stranded nucleic acid
JP2014528740A JP6112569B2 (ja) 2011-12-16 2012-12-17 キメラ２重鎖核酸

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017044034A Division JP6416301B2 (ja) 2011-12-16 2017-03-08 キメラ２重鎖核酸

Publications (3)

Publication Number Publication Date
JP2015502134A JP2015502134A (ja) 2015-01-22
JP2015502134A5 JP2015502134A5 (enExample) 2016-03-31
JP6112569B2 true JP6112569B2 (ja) 2017-04-12

Family

ID=47559626

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2014528740A Active JP6112569B2 (ja) 2011-12-16 2012-12-17 キメラ２重鎖核酸
JP2017044034A Active JP6416301B2 (ja) 2011-12-16 2017-03-08 キメラ２重鎖核酸
JP2018188022A Active JP6638923B2 (ja) 2011-12-16 2018-10-03 キメラ２重鎖核酸
JP2019224279A Active JP6960123B2 (ja) 2011-12-16 2019-12-12 キメラ２重鎖核酸
JP2020179738A Active JP7174384B2 (ja) 2011-12-16 2020-10-27 キメラ２重鎖核酸
JP2021136038A Pending JP2022000426A (ja) 2011-12-16 2021-08-24 キメラ２重鎖核酸
JP2022146970A Active JP7423015B2 (ja) 2011-12-16 2022-09-15 キメラ２重鎖核酸

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2017044034A Active JP6416301B2 (ja) 2011-12-16 2017-03-08 キメラ２重鎖核酸
JP2018188022A Active JP6638923B2 (ja) 2011-12-16 2018-10-03 キメラ２重鎖核酸
JP2019224279A Active JP6960123B2 (ja) 2011-12-16 2019-12-12 キメラ２重鎖核酸
JP2020179738A Active JP7174384B2 (ja) 2011-12-16 2020-10-27 キメラ２重鎖核酸
JP2021136038A Pending JP2022000426A (ja) 2011-12-16 2021-08-24 キメラ２重鎖核酸
JP2022146970A Active JP7423015B2 (ja) 2011-12-16 2022-09-15 キメラ２重鎖核酸

Country Status (9)

Country Link
US (6) US9816089B2 (enExample)
EP (1) EP2791335B1 (enExample)
JP (7) JP6112569B2 (enExample)
CN (2) CN112386605A (enExample)
AU (1) AU2012353330B2 (enExample)
CA (2) CA3106312C (enExample)
ES (1) ES2707232T3 (enExample)
IN (1) IN2014CN04590A (enExample)
WO (1) WO2013089283A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016526529A (ja) * 2013-06-16 2016-09-05 国立大学法人 東京医科歯科大学 エクソンスキッピング効果を有する二本鎖アンチセンス核酸

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 官能化核酸の合成のための方法
CN112386605A (zh) * 2011-12-16 2021-02-23 国立大学法人东京医科齿科大学 嵌合的双链核酸
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
AU2014222150A1 (en) * 2013-03-01 2015-09-10 National University Corporation Tokyo Medical And Dental University Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
WO2014148620A1 (ja) * 2013-03-21 2014-09-25 国立大学法人東京医科歯科大学 二重鎖核酸結合剤、当該結合剤－二重鎖核酸複合体、当該複合体を含有する医薬品組成物、及び、当該複合体の製造方法
WO2015105083A1 (ja) * 2014-01-07 2015-07-16 塩野義製薬株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
EP3929293A3 (en) 2015-04-03 2022-03-16 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
US11116843B2 (en) 2015-09-25 2021-09-14 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
WO2017068791A1 (ja) * 2015-10-23 2017-04-27 レナセラピューティクス株式会社 少なくとも１つのバルジ構造を有する核酸複合体
JPWO2017068790A1 (ja) * 2015-10-23 2018-08-09 レナセラピューティクス株式会社 核酸複合体
WO2017094745A1 (ja) * 2015-12-01 2017-06-08 国立大学法人大阪大学 核酸を含む経腸投与用組成物
JP6988481B2 (ja) 2016-01-26 2022-01-05 日産化学株式会社 一本鎖オリゴヌクレオチド
MA45328A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
JP7043078B2 (ja) * 2016-09-23 2022-03-29 国立大学法人 東京医科歯科大学 血液脳関門通過型ヘテロ２本鎖核酸
WO2018062510A1 (ja) 2016-09-29 2018-04-05 国立大学法人東京医科歯科大学 オーバーハングを有する二本鎖核酸複合体
CA3052801A1 (en) * 2017-02-06 2018-08-09 Nissan Chemical Corporation Single-stranded oligonucleotide
US11638717B2 (en) 2017-03-29 2023-05-02 Shionogi & Co., Ltd. Complex of nucleic acid medicine and multibranched lipid
EP3604531A4 (en) * 2017-03-31 2020-12-23 Aichi Medical University NUCLEIC ACID ANTISENS FOR INHIBITION OF CHONDROITIN SULPHATE BIOSYNTHESIS
JP6974872B2 (ja) * 2017-06-30 2021-12-01 国立大学法人 東京医科歯科大学 ヘテロ二本鎖型ａｎｔｉｍｉＲ
CA3070809A1 (en) 2017-07-26 2019-01-31 Nissan Chemical Corporation Single-stranded oligonucleotide
US11725208B2 (en) 2017-12-14 2023-08-15 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US11674141B2 (en) 2018-02-28 2023-06-13 National University Corporation Tokyo Medical And Dental University Ischemic-lesion-site-specific gene therapy
KR20190110043A (ko) * 2018-03-19 2019-09-27 주식회사 케이티 비디오 신호 처리 방법 및 장치
EP3769769A4 (en) * 2018-03-19 2022-05-04 National University Corporation Tokyo Medical and Dental University NUCLEIC ACID WITH REDUCED TOXICITY
CA3094303A1 (en) 2018-03-20 2019-09-26 Tokyo Institute Of Technology Antisense oligonucleotide reduced in toxicity
EP3770257B1 (en) * 2018-03-22 2026-01-28 Institute Of Science Tokyo Bbb-passing lipid ligand of hetero nucleic acid
CN113614232A (zh) * 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
JP7687682B2 (ja) * 2019-04-08 2025-06-03 国立大学法人東京科学大学 筋疾患治療用医薬組成物
EP4005602A4 (en) 2019-07-30 2024-06-12 Shionogi & Co., Ltd NUCLEIC ACID AGENT TARGETED AGAINST MURF1
EP4043565A4 (en) * 2019-10-11 2024-01-24 National University Corporation Tokyo Medical and Dental University MODIFIED HETERONUCLEIC ACID
EP4090744A4 (en) * 2020-01-17 2024-04-10 Anastasia Khvorova UNIVERSAL DYNAMIC PHARMACOKINETIC MODIFYING ANCHORS
CN114929876A (zh) 2020-01-31 2022-08-19 株式会社三和化学研究所 Atn1的反义寡核苷酸
JPWO2021177418A1 (enExample) 2020-03-04 2021-09-10
WO2021187392A1 (ja) 2020-03-16 2021-09-23 国立大学法人東京医科歯科大学 モルホリノ核酸を含むヘテロ核酸
WO2021242883A1 (en) 2020-05-26 2021-12-02 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
JP7751302B2 (ja) 2020-06-15 2025-10-08 リードファーマ株式会社 架橋型ヌクレオシドおよびヌクレオチド
WO2022106695A1 (en) 2020-11-23 2022-05-27 Alpha Anomeric Sas Nucleic acid duplexes
US20240141414A1 (en) * 2021-02-26 2024-05-02 Northwestern University Cell-free biosensors with dna strand displacement circuits
WO2022250050A1 (ja) 2021-05-25 2022-12-01 国立大学法人東京医科歯科大学 ｓｃｐＢＮＡ又はＡｍＮＡを含むヘテロ核酸
US20240279655A1 (en) 2021-05-31 2024-08-22 Rena Therapeutics Inc. Ligand-binding nucleic acid complex
EP4389891A4 (en) * 2021-08-19 2025-10-29 Univ Nat Corp Tokyo Medical & Dental MODIFIED HETERONUCLEIC ACID CONTAINING MORPHOLINO NUCLEIC ACID
JPWO2023026994A1 (enExample) 2021-08-21 2023-03-02
WO2023042876A1 (ja) 2021-09-15 2023-03-23 国立大学法人東京医科歯科大学 ２'－修飾ヌクレオシドを含むヘテロ核酸
EP4415827A4 (en) * 2021-10-14 2025-12-03 Univ Arizona State PROGRAMMABLE DISTRIBUTION PLATFORMS FOR RNA STRUCTURES
JPWO2023080159A1 (enExample) 2021-11-02 2023-05-11
JP7412668B2 (ja) * 2021-12-07 2024-01-15 リードファーマ株式会社 アンチセンスオリゴヌクレオチド複合体
WO2024071099A1 (ja) 2022-09-29 2024-04-04 国立大学法人東京医科歯科大学 ５'－シクロプロピレン修飾を含む核酸分子
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
WO2024228398A1 (ja) * 2023-05-02 2024-11-07 国立大学法人東京医科歯科大学 グアニン四重鎖構造を誘導するための核酸剤

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110894A (ja) * 1995-10-17 1997-04-28 Soyaku Gijutsu Kenkyusho:Kk ハイブリッドｄｎａ／ｒｎａオリゴヌクレオチド及び抗ウイルス剤
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP3781879B2 (ja) 1996-11-18 2006-05-31 武 今西 新規ヌクレオチド類縁体
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
EP2253639A1 (en) 1997-09-12 2010-11-24 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
US20060074034A1 (en) * 2001-09-17 2006-04-06 Collins Douglas A Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
FR2832154B1 (fr) * 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
AU2002249967A1 (en) * 2001-11-12 2003-05-26 Epiclone, Inc. Gene silencing using sense dna and antisense rna hybrid constructs
AU2003247521A1 (en) * 2002-06-26 2004-01-19 Isis Pharmaceuticals, Inc. Antisense inhibition via rnase h-independent reduction in mrna
DE10240417A1 (de) * 2002-09-02 2004-03-11 Avontec Gmbh Decoy-Oligonukleotid-Hemmung der CD40-Expression
AU2003273336A1 (en) * 2002-09-18 2004-04-08 Isis Pharmaceuticals, Inc. Efficient reduction of target rna's by single- and double-stranded oligomeric compounds
EP2336318B1 (en) 2002-11-13 2013-04-24 Genzyme Corporation Antisense modulation of apolipoprotein b expression
ES2382807T3 (es) 2003-08-28 2012-06-13 Takeshi Imanishi Nuevos ácidos nucleicos artificiales del tipo de enlace N-O con reticulación
PE20050469A1 (es) * 2003-09-18 2005-09-10 Lilly Co Eli Modulacion de la expresion de eif4e
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
AU2011204898A1 (en) * 2004-04-09 2011-08-11 Biodelivery Sciences International, Inc Nucleotide-cochleate compositions and methods of use
US20080199960A1 (en) * 2004-05-13 2008-08-21 Juliano Rudolph L Methods for the Delivery of Oligomeric Compounds
EP1838875A4 (en) * 2004-12-30 2010-08-25 Todd M Hauser COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION USING SELF-PROTECTED OLIGONUCLEOTIDES
ATE514777T1 (de) 2006-05-05 2011-07-15 Isis Pharmaceuticals Inc Verbindungen und verfahren zur modulation von genexpression
KR20090064378A (ko) * 2006-08-10 2009-06-18 온코세라피 사이언스 가부시키가이샤 유방암 관련 유전자 및 폴리펩티드
WO2008029619A1 (fr) 2006-09-07 2008-03-13 Daiichi Sankyo Company, Limited Oligonucléotide antisens ena ayant une action spécifique de la séquence
ES2603379T3 (es) 2006-10-09 2017-02-27 Roche Innovation Center Copenhagen A/S Compuestos antagonistas de ARN para la modulación de PCSK9
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US7858592B2 (en) * 2007-02-26 2010-12-28 The Board Of Regents Of The University Of Texas System Interfering RNAs against the promoter region of P53
US8461124B2 (en) * 2007-03-15 2013-06-11 Jyoti Chattopadhyaya Five- and six-membered conformationally locked 2′,4′-carbocyclic ribo-thymidines for the treatment of infections and cancer
CN101980726A (zh) * 2008-02-08 2011-02-23 普罗森那控股公司 治疗与dna重复不稳定性相关的遗传病症的方法和装置
EP2133425A1 (en) 2008-06-13 2009-12-16 Karin Mölling Method and compound for antiviral (HIV) therapy
US8541569B2 (en) * 2008-09-06 2013-09-24 Chemgenes Corporation Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA
EP3252068B1 (en) * 2009-10-12 2025-07-02 Larry J. Smith Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
CN112386605A (zh) * 2011-12-16 2021-02-23 国立大学法人东京医科齿科大学 嵌合的双链核酸
CA2913499A1 (en) * 2013-05-30 2014-12-04 National University Corporation Tokyo Medical And Dental University Double-stranded agents for delivering therapeutic oligonucleotides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016526529A (ja) * 2013-06-16 2016-09-05 国立大学法人 東京医科歯科大学 エクソンスキッピング効果を有する二本鎖アンチセンス核酸

Also Published As

Publication number Publication date
CA3106312A1 (en) 2013-06-20
US10337006B2 (en) 2019-07-02
CA2859581C (en) 2022-03-22
JP2022171811A (ja) 2022-11-11
WO2013089283A1 (en) 2013-06-20
US20180320181A1 (en) 2018-11-08
JP2022000426A (ja) 2022-01-04
CN112386605A (zh) 2021-02-23
US12344841B2 (en) 2025-07-01
JP6638923B2 (ja) 2020-02-05
JP2017140031A (ja) 2017-08-17
US11034955B2 (en) 2021-06-15
US20180073024A1 (en) 2018-03-15
US20190270996A1 (en) 2019-09-05
JP7174384B2 (ja) 2022-11-17
ES2707232T3 (es) 2019-04-03
CN104126010A (zh) 2014-10-29
EP2791335A1 (en) 2014-10-22
CN104126010B (zh) 2021-04-06
US10329567B2 (en) 2019-06-25
IN2014CN04590A (enExample) 2015-09-18
US20210340540A1 (en) 2021-11-04
JP2020039364A (ja) 2020-03-19
JP6416301B2 (ja) 2018-10-31
US9816089B2 (en) 2017-11-14
US20140302603A1 (en) 2014-10-09
JP7423015B2 (ja) 2024-01-29
JP6960123B2 (ja) 2021-11-05
JP2018203779A (ja) 2018-12-27
US20240158790A1 (en) 2024-05-16
AU2012353330A1 (en) 2014-07-31
CA3106312C (en) 2025-09-23
EP2791335B1 (en) 2018-11-14
JP2015502134A (ja) 2015-01-22
JP2021011501A (ja) 2021-02-04
AU2012353330B2 (en) 2018-04-19
CA2859581A1 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
JP7174384B2 (ja) キメラ２重鎖核酸
JP6440170B2 (ja) キメラ一本鎖アンチセンスポリヌクレオチドおよび二本鎖アンチセンス剤
WO2020196662A1 (ja) 二本鎖核酸複合体及びその使用
EP4446414A1 (en) Antisense oligonucleotide complex
EP4680249A1 (en) Rnai agents for inhibiting expression of mitochondrial amidoxime reducing component 1 (marc1), pharmaceutical compositions thereof, and methods of use
HK40084771B (zh) 用於抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法
WO2020262555A1 (ja) 核酸医薬副作用軽減剤、該核酸医薬副作用軽減剤を含む医薬組成物、並びに核酸医薬の副作用惹起性を軽減する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140709

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20140811

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150826

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20151006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170308

R150 Certificate of patent or registration of utility model

Ref document number: 6112569

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350